Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth W Mahaffey

Showing results (391-400 of 635) with videos related to

Pageof 64
Sort By:
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 25, 2012
Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trialGlenn M Chertow, Ricardo Correa-Rotter, Geoffrey A Block, et al.
American Heart Journal|July 29, 2014
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II: rationale and design of the ORBIT-AF II registryBenjamin A Steinberg, Rosalia G Blanco, Donna Ollis, et al.
Journal of the American College of Cardiology|March 19, 2013
Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trialJonathan P Piccini, Susanna R Stevens, Yuliya Lokhnygina, et al.
Journal of the American Heart Association|May 30, 2026
Association Between Predicting Risk of Cardiovascular Disease Events (PREVENT) Risk Scores and Subclinical Cardiovascular Disease: Insights From the Project Baseline Health StudyGracia Fahed, Diona Gjermeni, Nicholas Cauwenberghs, et al.
JACC. Heart Failure|March 14, 2014
Heart failure complicating non-ST-segment elevation acute coronary syndrome: timing, predictors, and clinical outcomesMaria Cecilia Bahit, Renato D Lopes, Robert M Clare, et al.
Stroke|April 26, 2014
Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trialKa Sing Lawrence Wong, Dai Yi Hu, Abraham Oomman, et al.
Circulation|May 11, 2012
Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attackStefan K James, Robert F Storey, Nardev S Khurmi, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|May 14, 2016
Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AFAdam D DeVore, Anne S Hellkamp, Richard C Becker, et al.
Circulation|July 13, 2016
Response by Piccini et al to Letters Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation"Jonathan P Piccini, Anne S Hellkamp, Jeffrey B Washam, et al.
Circulation. Heart Failure|June 1, 2013
Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AFSean van Diepen, Anne S Hellkamp, Manesh R Patel, et al.
Pageof 64

Showing results (391-400 of 635) with videos related to

Sort By:
Pageof 64
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 25, 2012
Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trialGlenn M Chertow, Ricardo Correa-Rotter, Geoffrey A Block, et al.
American Heart Journal|July 29, 2014
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II: rationale and design of the ORBIT-AF II registryBenjamin A Steinberg, Rosalia G Blanco, Donna Ollis, et al.
Journal of the American College of Cardiology|March 19, 2013
Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trialJonathan P Piccini, Susanna R Stevens, Yuliya Lokhnygina, et al.
Journal of the American Heart Association|May 30, 2026
Association Between Predicting Risk of Cardiovascular Disease Events (PREVENT) Risk Scores and Subclinical Cardiovascular Disease: Insights From the Project Baseline Health StudyGracia Fahed, Diona Gjermeni, Nicholas Cauwenberghs, et al.
JACC. Heart Failure|March 14, 2014
Heart failure complicating non-ST-segment elevation acute coronary syndrome: timing, predictors, and clinical outcomesMaria Cecilia Bahit, Renato D Lopes, Robert M Clare, et al.
Stroke|April 26, 2014
Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trialKa Sing Lawrence Wong, Dai Yi Hu, Abraham Oomman, et al.
Circulation|May 11, 2012
Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attackStefan K James, Robert F Storey, Nardev S Khurmi, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|May 14, 2016
Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AFAdam D DeVore, Anne S Hellkamp, Richard C Becker, et al.
Circulation|July 13, 2016
Response by Piccini et al to Letters Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation"Jonathan P Piccini, Anne S Hellkamp, Jeffrey B Washam, et al.
Circulation. Heart Failure|June 1, 2013
Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AFSean van Diepen, Anne S Hellkamp, Manesh R Patel, et al.
Pageof 64